Trials / Completed
CompletedNCT01556451
ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)
An Open-label, Single-arm, Multi-center, Phase IV Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ in Healthy Adults in Korea
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ in Korean adults. Approximately 180 herpes zoster history negative subjects ≥ 50 years of age will be enrolled in the study. Each subject will receive a single dose of ZOSTAVAX™. No statistical hypothesis testing will be conducted in the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Zoster Vaccine Live | Zoster vaccine live |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2012-03-16
- Last updated
- 2017-04-12
- Results posted
- 2013-09-23
Source: ClinicalTrials.gov record NCT01556451. Inclusion in this directory is not an endorsement.